HARP Harpoon Therapeutics, Inc.: מחיר חזוי לרווח

Harpoon Therapeutics (HARP) is developing an oncology environment based on TriTAC, establishing closed licensing agreements with pharmaceutical behemoths. The company's forward P/E ratio history demonstrates market expectations, where the 0.00 metric reflects current dynamics. Diversification of the drug portfolio to combat various tumors mitigates risks, while the full integration of expert staff into Merck structures ensures the preservation of key competencies.

Forward P/E determines the market value of a share relative to expected net income, measuring the business's ability to generate revenue and service debt. The current value of 0.00 for the issuer's forward P/E allows for an assessment of the capitalization efficiency of Harpoon Therapeutics (HARP), taking into account the costs of environmental modernization of laboratories and the implementation of safe chemical disposal within the framework of onco-immunology research.